News

MedAlliance’s SELUTION SLR™ Receives Second FDA IDE Approval

9 August 2022 – SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). This comes only a few months after the company received IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications (May 2022).

read more

First Patient Enrolled in SELUTION SLR IDE BTK Study

7 June 2022 – The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, just one week after receiving IDE approval.

read more

MedAlliance’s SELUTION SLR™ drug-eluting balloon (DEB) receives FDA Investigational Device Exemption (IDE) approval, making it the first limus DEB to be available to US patients

26 May 2022 – The SELUTION SLR™ (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR was also the first DEB granted “Breakthrough Device Designation” by the FDA on March 4, 2019 and further on September 25, 2019 for below-the-knee (BTK) indications in peripheral artery disease.

read more

MedAlliance Acquires Japanese Partner MDK Medical

2 February 2022 – Swiss-based medical technology company MedAlliance has acquired its partner MDK Medical, a Japanese vascular specialist company. MDK Medical has previously worked closely with MedAlliance in developing Japanese clinical studies for its novel sirolimus Drug Eluting Balloon (DEB) SELUTION SLR™ in the treatment of peripheral arterial disease (PAD).

read more